BioAffinity Financial Statements From 2010 to 2024

BIAF Stock  USD 1.17  0.02  1.68%   
BioAffinity Technologies, financial statements provide useful quarterly and yearly information to potential bioAffinity Technologies, investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioAffinity Technologies, financial statements helps investors assess BioAffinity Technologies,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioAffinity Technologies,'s valuation are summarized below:
Profit Margin
(1.19)
Market Capitalization
19.8 M
Enterprise Value Revenue
2.0492
Revenue
7.3 M
Earnings Share
(0.91)
There are over one hundred nineteen available fundamental signals for bioAffinity Technologies,, which can be analyzed over time and compared to other ratios. Active traders should verify all of bioAffinity Technologies, prevailing fundamental drivers against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. Enterprise Value is estimated to decrease to about 11 M

BioAffinity Technologies, Total Revenue

2.66 Million

Check BioAffinity Technologies, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 262.1 K, Interest Expense of 35.3 K or Gross Profit of 831.2 K, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0 or PTB Ratio of 2.78. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies, Valuation or Volatility modules.
  
Check out the analysis of BioAffinity Technologies, Correlation against competitors.
For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.

BioAffinity Technologies, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsM8.2 M2.2 M
Slightly volatile
Short and Long Term Debt Total1.5 M1.6 M4.3 M
Very volatile
Other Current Liabilities702.8 K689.6 K687.6 K
Slightly volatile
Total Current Liabilities2.1 M2.2 M5.1 M
Very volatile
Property Plant And Equipment Net2.1 MM307.1 K
Slightly volatile
Accounts Payable324.5 K604.8 K182 K
Slightly volatile
Cash3.6 M2.8 M1.7 M
Slightly volatile
Non Current Assets Total4.5 M4.2 M625.7 K
Slightly volatile
Non Currrent Assets Other10 K16.1 K12.3 K
Pretty Stable
Cash And Short Term Investments3.6 M2.8 M1.7 M
Slightly volatile
Net Receivables852.3 K811.7 K112.9 K
Slightly volatile
Common Stock Shares Outstanding5.7 M8.7 M7.2 M
Slightly volatile
Liabilities And Stockholders EquityM8.2 M2.2 M
Slightly volatile
Other Current Assets220.1 K321 K103.9 K
Slightly volatile
Other Stockholder Equity27.2 M49.4 M14.2 M
Slightly volatile
Total Liabilities6.7 M3.4 MM
Pretty Stable
Total Current AssetsMM1.8 M
Slightly volatile
Short Term Debt874.3 K920.3 K4.2 M
Very volatile
Common Stock39.7 K65.8 K25.9 K
Slightly volatile
Other Assets11.2 K9.4 K15.6 K
Slightly volatile
Long Term Debt117.5 K184.2 K80.7 K
Slightly volatile
Non Current Liabilities TotalM1.1 M3.5 M
Slightly volatile
Inventory24.8 K18.5 K28.8 K
Very volatile
Property Plant And Equipment Gross2.5 M2.4 M566.8 K
Slightly volatile
Short and Long Term Debt215.2 K226.6 K8.1 M
Slightly volatile
Capital Stock44.5 K65.8 K26.2 K
Slightly volatile
Property Plant Equipment5.6 K4.2 K8.2 K
Slightly volatile
Deferred Long Term Liabilities6.4 K7.1 K7.8 K
Slightly volatile
Current Deferred Revenue26.4 K29.8 K32.4 K
Slightly volatile
Intangible Assets666.8 K750.1 K816.8 K
Slightly volatile

BioAffinity Technologies, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization262.1 K249.6 K63.4 K
Slightly volatile
Interest Expense35.3 K37.1 K409.2 K
Slightly volatile
Other Operating Expenses11 M10.5 M4.1 M
Slightly volatile
Research Development1.2 M1.7 M1.7 M
Slightly volatile
Cost Of Revenue1.8 M1.7 M266.6 K
Slightly volatile
Total Operating Expenses4.5 M8.8 M3.5 M
Slightly volatile
Income Tax Expense22 K21 K5.5 K
Slightly volatile
Tax Provision19.6 K18.7 K4.9 K
Slightly volatile
Interest Income155.8 K148.4 K24.2 K
Slightly volatile
Selling General Administrative7.1 M6.8 M1.9 M
Slightly volatile
Reconciled Depreciation113.5 K108.1 K32.1 K
Slightly volatile

BioAffinity Technologies, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change In Working Capital539.5 K900.8 K392.7 K
Slightly volatile
Begin Period Cash Flow12 M11.4 M2.2 M
Slightly volatile
Depreciation262.1 K249.6 K63.4 K
Slightly volatile
End Period Cash Flow3.6 M2.8 M1.7 M
Slightly volatile
Net Borrowings2.9 MM2.2 M
Slightly volatile
Stock Based Compensation786.3 K748.8 K324 K
Slightly volatile
Change To Operating Activities543.6 K682.9 K450.4 K
Slightly volatile
Change To Netincome3.1 M2.8 M4.2 M
Slightly volatile
Change To Liabilities50.8 K35.1 K75.4 K
Slightly volatile
Dividends Paid148166181
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.825.07751.3 K
Slightly volatile
Days Sales Outstanding111117706
Slightly volatile
Average Payables242.7 K474.9 K194.3 K
Slightly volatile
Stock Based Compensation To Revenue0.280.295744.895
Slightly volatile
Capex To Depreciation0.08720.09183.09
Slightly volatile
Inventory Turnover98.8994.183313.4569
Slightly volatile
Days Of Inventory On Hand3.683.8754993
Slightly volatile
Payables Turnover3.022.87850.6621
Slightly volatile
Sales General And Administrative To Revenue454511556
Slightly volatile
Research And Ddevelopement To Revenue0.650.681233
Slightly volatile
Capex To Revenue0.00860.00939.6962
Slightly volatile
Cash Per Share0.50.32260.2893
Slightly volatile
Days Payables Outstanding12012720 K
Slightly volatile
Income Quality0.420.76070.6558
Slightly volatile
Intangibles To Total Assets0.220.240.2666
Slightly volatile
Current Ratio2.01.76741.0472
Slightly volatile
Receivables Turnover3.283.12010.8235
Slightly volatile
Graham Number4.623.36623.6425
Slightly volatile
Capex Per Share0.00250.00260.0079
Slightly volatile
Average Receivables431.6 K411.1 K61.4 K
Slightly volatile
Revenue Per Share0.30.28950.0402
Slightly volatile
Interest Debt Per Share0.0540.05690.6361
Very volatile
Debt To Assets0.05320.0569.1705
Very volatile
Operating Cycle1151214.5 K
Slightly volatile
Days Of Payables Outstanding12012720 K
Slightly volatile
Ebt Per Ebit0.940.99281.3538
Slightly volatile
Quick Ratio2.01.75911.0458
Slightly volatile
Net Income Per E B T0.81.00270.9876
Slightly volatile
Cash Ratio1.841.25520.9642
Slightly volatile
Days Of Inventory Outstanding3.683.8754993
Slightly volatile
Days Of Sales Outstanding111117706
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.00380.9986
Pretty Stable
Fixed Asset Turnover1.331.26960.1927
Slightly volatile
Debt Ratio0.05320.0569.1705
Very volatile
Price Sales Ratio4.825.07751.3 K
Slightly volatile
Asset Turnover0.320.3080.0422
Slightly volatile
Gross Profit Margin0.30.31260.8232
Slightly volatile

BioAffinity Technologies, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap12.2 M12.9 M51.1 M
Slightly volatile

BioAffinity Fundamental Market Drivers

Cash And Short Term Investments2.8 M

BioAffinity Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About BioAffinity Technologies, Financial Statements

BioAffinity Technologies, stakeholders use historical fundamental indicators, such as BioAffinity Technologies,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although BioAffinity Technologies, investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioAffinity Technologies,'s assets and liabilities are reflected in the revenues and expenses on BioAffinity Technologies,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in bioAffinity Technologies,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue29.8 K26.4 K
Cost Of Revenue1.7 M1.8 M
Total Revenue2.5 M2.7 M
Stock Based Compensation To Revenue 0.30  0.28 
Sales General And Administrative To Revenue 511.01  454.22 
Research And Ddevelopement To Revenue 0.68  0.65 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.29  0.30 
Ebit Per Revenue(3.15)(3.31)

Currently Active Assets on Macroaxis

When determining whether bioAffinity Technologies, is a strong investment it is important to analyze BioAffinity Technologies,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies,'s future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:
Check out the analysis of BioAffinity Technologies, Correlation against competitors.
For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.91)
Revenue Per Share
0.744
Quarterly Revenue Growth
120.474
Return On Assets
(0.70)
Return On Equity
(1.52)
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.